Trailing-twelve-month (TTM) revenue is $1.22 Billion with a year-over-year growth of (0.38%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q1 FY2026Period ended 2025-09-30 | $286,555,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q2 FY2026Period ended 2025-12-31 | $295,877,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-04 |
| Q3 FY2026Period ended 2026-03-31 | $311,415,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q4 FY2026Period ended 2026-06-30 | $321,192,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-24 |
| TTM revenue | $1,215,039,000 |
Current P/S: $11,368,475,090 market capitalization ÷ $1,215,039,000 TTM revenue = 9.36x.
Market capitalization source: FMP quote. Quote observed 2026-09-25T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q4 FY2026 (2026-06-30): $321.19M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-26T00:16:11.190Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2026-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20132013-06-30 · USD | FY20142014-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD | FY20252025-06-30 · USD | FY20262026-06-30 · USD |
|---|---|---|---|---|---|---|
| Biotechnology | $288M | $301M | N/A | N/A | N/A | N/A |
| Clinical Controls | $22M | $57M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20132013-06-30 · USD | FY20142014-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD | FY20252025-06-30 · USD | FY20262026-06-30 · USD |
|---|---|---|---|---|---|---|
| APAC, excluding Greater China | N/A | N/A | $73M | $74M | $77M | $86M |
| C N | $14M | $19M | $114M |
$1.22B
$1.22 Billion
(0.38%)
vs. $1.22B a year ago (TTM)
+5.47%
5 Year compound annual growth rate
1 Year
(0.38%)
3 Year
+2.25%
5 Year
+5.47%
10 Year
+9.31%
15 Year
+10.02%
20 Year
+9.37%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $1.22B | ($4.60M) | (0.38%) |
| 2025 | $1.22B | +$60.58M | +5.23% |
| 2024 | $1.16B | +$22.36M | +1.97% |
| 2023 | $1.14B | +$31.10M | +2.81% |
| 2022 | $1.11B | +$174.57M | +18.75% |
| 2021 |
TTM Growth
(0.38%)
3-Year CAGR
+2.25%
5-Year CAGR
+5.47%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-26T00:16:11.190Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| N/A |
| Consumables | N/A | N/A | $918M | $928M | $972M | $985M |
|---|
| Instruments | N/A | N/A | $112M | $108M | $112M | $111M |
|---|
| Royalty | N/A | N/A | $21M | $23M | $24M | $25M |
|---|
| $100M |
| $104M |
| Europe | $88M | $97M | $220M | $241M | $266M | $294M |
|---|
| Other Asia | $29M | $33M | N/A | N/A | N/A | N/A |
|---|
| Rest Of World | $15M | $19M | $37M | $36M | $38M | $39M |
|---|
| U S | $164M | $190M | $642M | $658M | $683M | $635M |
|---|
| United Kingdom | N/A | N/A | $49M | $50M | N/A | N/A |
|---|
| UNITED KINGDOM | N/A | N/A | N/A | N/A | $55M | $56M |
|---|
| $931.03M |
| +$192.34M |
| +26.04% |
| 2020 | $738.69M | +$24.68M | +3.46% |
| 2019 | $714.01M | +$71.01M | +11.04% |
| 2018 | $642.99M | +$79.99M | +14.21% |
| 2017 | $563.00M | +$63.98M | +12.82% |
